Gemtuzumab ozogamicin in acute myeloid leukemia revisited
F Thol, RF Schlenk - Expert opinion on biological therapy, 2014 - Taylor & Francis
Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults
BH Goldenson, AM Goodman… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
J Baron, ES Wang - Expert review of clinical pharmacology, 2018 - Taylor & Francis
Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
M Swaminathan, JE Cortes - Therapeutic Advances in …, 2023 - journals.sagepub.com
Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal
antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially …
antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially …
Therapeutic targeting of acute myeloid leukemia by gemtuzumab ozogamicin
M Gottardi, G Simonetti, A Sperotto, D Nappi… - Cancers, 2021 - mdpi.com
Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …
Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia
C Fenton, CM Perry - Drugs, 2005 - Springer
Gemtuzumab ozogamicin (Mylotarg®) is a conjugate of a monoclonal antibody and
calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid …
calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid …
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
AK Burnett, RK Hills, D Milligan, L Kjeldsen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
IA Voutsadakis - Anti-Cancer Drugs, 2002 - journals.lww.com
Abstract Gemtuzumab Ozogamicin (GO, CMA-676) is a monoclonal antibody against the
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
JM Rowe, B Löwenberg - Blood, The Journal of the American …, 2013 - ashpublications.org
Despite living in an era of unprecedented progress in the understanding of the genetic and
molecular biology of acute myeloid leukemia (AML), this has not translated into significant …
molecular biology of acute myeloid leukemia (AML), this has not translated into significant …
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse
EL Sievers - Expert opinion on biological therapy, 2001 - Taylor & Francis
Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …